Dermatitis herpetiformis

Dermatitis herpetiformis (DH), also known as Duhring disease or Duhring-Brocq disease, is a chronic autoimmune blistering skin disorder that is considered the cutaneous manifestation of celiac disease (gluten-sensitive enteropathy). It is characterized by intensely pruritic (itchy) papulovesicular eruptions that typically appear symmetrically on the extensor surfaces of the body, including the elbows, knees, buttocks, back, and scalp. Despite its name, dermatitis herpetiformis has no relation to herpes virus infection; the term 'herpetiformis' refers to the grouped (herpetiform) arrangement of the skin lesions. The hallmark diagnostic finding is granular deposits of immunoglobulin A (IgA) at the dermal-epidermal junction, detected by direct immunofluorescence of perilesional skin biopsy. DH primarily affects the skin and the gastrointestinal system. Although the majority of patients with DH have underlying small bowel villous atrophy consistent with celiac disease, many are asymptomatic from a gastrointestinal standpoint. The condition is strongly associated with HLA-DQ2 and HLA-DQ8 haplotypes, reflecting its shared genetic susceptibility with celiac disease. Patients may also be at increased risk for other autoimmune conditions, including thyroid disease, type 1 diabetes mellitus, and pernicious anemia. The disease is more common in individuals of Northern European descent and affects men slightly more often than women. The primary treatment for dermatitis herpetiformis is a strict, lifelong gluten-free diet (GFD), which addresses both the skin and intestinal manifestations of the disease. Adherence to a GFD can lead to complete resolution of the rash, though this may take months to years. For more rapid symptom control, dapsone (diaminodiphenyl sulfone) is the first-line pharmacological therapy and typically provides relief from itching and skin lesions within days. Patients on dapsone require regular monitoring for potential side effects, including hemolytic anemia and methemoglobinemia. Alternative medications such as sulfasalazine or sulfapyridine may be used in patients who cannot tolerate dapsone. With appropriate management, the prognosis is excellent, though the condition is generally considered lifelong.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Dermatitis herpetiformis